Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis

Inclusion criteria

• . Healthy male or female subjects, aged 18-45 years (including critical values);
• . Body mass index (BMI) between 18 and 26kg/m2 (including critical values), with male weight ≥ 50kg and female weight ≥ 45kg;
• . All women and men with fertility potential must be willing to use at least one efficient method of contraception from the signing of the informed consent form until 3 months after the last administration of the study drug, as detailed in Appendix 5;
• . Voluntarily participate in the experiment and sign an informed consent form;
• . Subjects who are able to communicate well with the researcher and are willing and able to comply with all planned visits, treatment plans, laboratory tests, and other research procedures
• . When informed consent is given, the age range is between 18 and 75 years (including the boundary value), regardless of gender;
• . Body mass index (BMI) between 18 and 26kg/m2 (including critical values), with male weight ≥ 50kg and female weight ≥ 45kg;
• . Before administration, the diagnosis of mild to moderate atopic dermatitis should be met:

Exclusion criteria